How can China's rare disease industry take the next step to crack the "sky-price drug" crisis?

There is no medicine to cure, and there is no medicine to use.

In order to promote the development of China's rare disease industry, the 10th China Rare Disease Summit Forum was held in Hangzhou recently

What is the value of China's rare disease industry?

Hu Qicong believes that looking at the world, the rare disease industry has three major values: medical value, technical value and commercial value

At present, more than 7,000 rare diseases have been discovered in the world, of which only about 5% have effective treatment drugs, and most rare diseases still lack effective treatment methods

Corresponding to the unmet needs is the considerable success rate in the development of rare disease drugs

The vast market and the high rate of R&D success are these two factors that are attracting more and more companies to work in the field of rare diseases

In terms of commercial value, the market potential of the rare disease industry is also huge

Benchmarking the global market, China's rare diseases have a very broad future development space

The "three mountains" hindering the development of the rare disease industry

It is generally believed that there are "three mountains" in the development of China's rare disease industry: one is that there are few patients and the treatment cycle is short; the second is that the diagnosis and treatment capabilities are weak and the diagnosis cycle is long; the third is that the level of protection is low and the price of medicines is high.

Among the 121 rare diseases announced in China, 10 rare diseases have more than 100,000 patients, even more than some tumor patients

At present, it is an indisputable fact that the domestic ability to diagnose and treat rare diseases is weak

At the policy level, China's national rare disease registration system was officially launched in 2017; in 2018, the first national non-profit rare disease exchange platform-China Rare Disease Alliance was launched; in 2019, the first national rare disease diagnosis and treatment guideline "Rare Disease Diagnosis and Treatment Guide" (2019 version)" launched

In terms of medical security, Hu Qicong said that China's payment for rare diseases has reached a turning point

The future development trend of China's rare disease industry

In terms of industrial development trends, China’s rare disease industry is undergoing three major changes: dominated by foreign companies, to local pharmaceutical companies, and foreign companies are blooming; from generic drugs to “quick-following” and first-innovative drugs; from “special drugs” focusing on drug treatments Mode", shifting to an ecological model oriented to patient needs

Since 2015, more and more local pharmaceutical companies are deploying the rare disease market.

Undoubtedly, product innovation in the field of rare diseases in China is still in the 1.

Standing at a new point in time, Hu Qicong believes that the rare disease industry in the future must be an area with better policies, more attention to capital, and more talents
.
With the continuous development of the industry, there will be a group of local rare disease companies with an international perspective and facing the international market going out, bringing a series of original drugs and technologies with clinical value, and spawning the birth of a large number of rare disease patients.
Format and ecology
.